{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T10:07:44Z","timestamp":1713521264284},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>To evaluate the results of near confluent laser therapy versus combined less dense laser and intra vitreal bevacizumab in treatment of infants with type 1 retinopathy of prematurity (ROP) in zone II.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a prospective double-blinded randomized clinical trial study. Infants with Type 1 ROP in Zone 2 were randomized into case and control groups. Conventional laser therapy was executed for control group and combination of IVB and laser treatment was employed for the case group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eighty-six eyes from 43 infants were analyzed in this trial. The first group included 42 eyes from 21 infants receiving a combination of laser ablation and IVB. The second group contained 44 eyes from 22 infants who received only conventional laser therapy. The combined IVB and laser ablation group demonstrated the neovascularization regression (20 out of 21 infants) one week after the procedure. In the conventional laser therapy group, this regression was found in (12 out of 22 infants) within one week after laser therapy (<jats:italic>P<\/jats:italic>\u2009=\u20090.001). Plus disease regression was observed in 20 (20\/21) of combined treatment group and 7 infants (7\/22) of conventional laser treatment group after one week.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Combined less dense laser and bevacizumab treatment resulted in more rapid regression in comparison with the conventional laser treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>IRCT20201120049450N1, 27\/12\/2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02689-0","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T09:07:34Z","timestamp":1669626454000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Outcomes of near confluent laser versus combined less dense laser and bevacizumab treatment of prethreshold ROP Type 1 Zone 2: a randomized controlled trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Ehsan","family":"Namvar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Bolkheir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Emadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadkarim","family":"Johari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Hossein","family":"Nowroozzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"2689_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/00004397-199203210-00014","volume":"32","author":"DG Hunter","year":"1992","unstructured":"Hunter DG, Mukai S. Retinopathy of prematurity: pathogenesis, diagnosis, and treatment. Int Ophthalmol Clin. 1992;32:163\u201384.","journal-title":"Int Ophthalmol Clin"},{"key":"2689_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0161-6420(93)31665-9","volume":"100","author":"DB Schaffer","year":"1993","unstructured":"Schaffer DB, Palmer EA, Plotsky DF, et al. Prognostic factors in the natural course of retinopathy of prematurity. The cryotherapy for retinopathy of prematurity Cooperative group. Ophthalmology. 1993;100:230\u20137.","journal-title":"Ophthalmology"},{"issue":"1","key":"2689_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1542\/peds.2004-1413","volume":"116","author":"WV Good","year":"2005","unstructured":"Good WV, Hardy RJ, Dobson V, Palmer EA, Phelps DL, Quintos M, Tung B. Early Treatment for Retinopathy of Prematurity Cooperative Group. The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study. Pediatrics. 2005;116(1):15\u201323. https:\/\/doi.org\/10.1542\/peds.2004-1413 PMID: 15995025.","journal-title":"Pediatrics"},{"issue":"3","key":"2689_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/bjo.2007.126201","volume":"92","author":"EM Lad","year":"2008","unstructured":"Lad EM, Nguyen TC, Morton JM, Moshfeghi DM. Retinopathy of prematurity in the United States. Br J Ophthalmol. 2008;92(3):320\u20135. https:\/\/doi.org\/10.1136\/bjo.2007.126201 Erratum in: Br J Ophthalmol. 2010 Sep;94(9):1268. PMID: 18303153.","journal-title":"Br J Ophthalmol"},{"key":"2689_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jaapos.2013.12.003","volume":"18","author":"DH Shin","year":"2014","unstructured":"Shin DH, Kong M, Kim SJ, et al. Risk factors and rate of progression for zone I versus zone II type 1 retinopathy of prematurity. J AAPOS. 2014;18:124\u20138.","journal-title":"J AAPOS"},{"key":"2689_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","volume":"106","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1988","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Arch Ophthalmol. 1988;106:471\u20139.","journal-title":"Arch Ophthalmol"},{"key":"2689_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/archopht.1990.01070040047029","volume":"108","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1990","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: three-month outcome. Arch Ophthalmol. 1990;108:195\u2013204.","journal-title":"Arch Ophthalmol"},{"key":"2689_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/archopht.1990.01070120056029","volume":"108","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1990","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: one-year outcome-structure and function. Arch Ophthalmol. 1990;108:1408\u201316.","journal-title":"Arch Ophthalmol"},{"key":"2689_CR9","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1001\/archopht.1993.01090030057039","volume":"111","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1993","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: 3\u00bd-year outcome-structure and function. Arch Ophthalmol. 1993;111:339\u201344.","journal-title":"Arch Ophthalmol"},{"key":"2689_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1001\/archopht.1996.01100130413008","volume":"114","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1996","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: Snellen visual acuity and struc-tural outcome at 51\u20442 years after randomization. Arch Ophthalmol. 1996;114:417\u201324.","journal-title":"Arch Ophthalmol"},{"key":"2689_CR11","doi-asserted-by":"crossref","unstructured":"Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1988;106:471\u20139.","DOI":"10.1001\/archopht.1988.01060130517027"},{"key":"2689_CR12","doi-asserted-by":"crossref","unstructured":"Multicenter trial of cryotherapy for retinopathy of prematurity: three-month outcome. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1990;108:195\u2013204.","DOI":"10.1001\/archopht.1990.01070040047029"},{"key":"2689_CR13","doi-asserted-by":"crossref","unstructured":"Multicenter trial of cryotherapy for retinopathy of prematurity: one-year outcome\u2014structure and function. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1990;108:1408\u201316.","DOI":"10.1001\/archopht.1990.01070120056029"},{"key":"2689_CR14","doi-asserted-by":"crossref","unstructured":"The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol. 1984;102:1130\u2013113.","DOI":"10.1001\/archopht.1984.01040030908011"},{"issue":"7","key":"2689_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity. The International classification of retinopathy of prematurity revisited. Arch Ophthalmol. 2005;123(7):991\u20139.","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"2689_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/00055735-199306000-00013","volume":"4","author":"JA McNamara","year":"1993","unstructured":"McNamara JA. Laser treatment for retinopathy of prematurity. Curr Opin Ophthalmol. 1993;4(3):76\u201380.","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"2689_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/00055735-200106000-00003","volume":"12","author":"MJ Banach","year":"2001","unstructured":"Banach MJ, Berinstein DM. Laser therapy for retinopathy of prematurity. Curr Opin Ophthalmol. 2001;12(3):164\u201370.","journal-title":"Curr Opin Ophthalmol"},{"issue":"5","key":"2689_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/archopht.123.5.621","volume":"123","author":"KA Rezai","year":"2005","unstructured":"Rezai KA, et al. Near confluent laser photocoagulation for the treatment of threshold retinopathy of prematurity. Arch Ophthalmol. 2005;123(5):621\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"2689_CR19","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.ophtha.2004.06.021","volume":"111","author":"JL Prenner","year":"2004","unstructured":"Prenner JL, Capone A Jr, Trese MT. Visual outcomes after lens-sparing vitrectomy for stage 4A retinopathy of prematurity. Ophthalmology. 2004;111(12):2271\u20133.","journal-title":"Ophthalmology"},{"issue":"4","key":"2689_CR20","first-page":"615","volume":"119","author":"RS Kaiser","year":"2001","unstructured":"Kaiser RS, Trese MT. Iris atrophy, cataracts, and hypotony following peripheral ablation for threshold retinopathy of prematurity. Arch Ophthalmol. 2001;119(4):615\u20137.","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"2689_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S0002-9394(99)00475-4","volume":"129","author":"SR Lambert","year":"2000","unstructured":"Lambert SR, et al. Cataract and phthisis bulbi after laser photoablation for threshold retinopathy of prematurity. Am J Ophthalmol. 2000;129(5):585\u201391.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"2689_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3928\/0191-3913-19980501-17","volume":"35","author":"BD Simons","year":"1998","unstructured":"Simons BD, et al. Bilateral hyphemas and cataracts after diode laser retinal photoablation for retinopathy of prematurity. J Pediatr Ophthalmol Strabismus. 1998;35(3):185\u20137.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"issue":"3","key":"2689_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/IAE.0b013e318159ec39","volume":"28","author":"JR Gaitan","year":"2008","unstructured":"Gaitan JR, et al. Anterior segment ischemia following laser therapy for threshold retinopathy of prematurity. Retina. 2008;28(3):55\u20137.","journal-title":"Retina"},{"issue":"9","key":"2689_CR24","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","volume":"248","author":"JY Lee","year":"2010","unstructured":"Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol. 2010;248(9):1257\u201362.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"2689_CR25","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","volume":"245","author":"EJ Chung","year":"2007","unstructured":"Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007;245(11):1727\u201330.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"2689_CR26","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.ophtha.2011.04.028","volume":"118","author":"DM Moshfeghi","year":"2011","unstructured":"Moshfeghi DM, Berrocal AM. Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology. 2011;118(7):1227\u20138.","journal-title":"Ophthalmology"},{"issue":"8","key":"2689_CR27","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130(8):1000\u20136.","journal-title":"Arch Ophthalmol"},{"key":"2689_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1155\/2014\/257286","volume":"2014","author":"R Kim","year":"2014","unstructured":"Kim R, Kim YC. \u201cPosterior pole sparing laser photocoagulation combined with intravitreal bevacizumab injection in posterior retinopathy of prematurity,.\u201d J Ophthalmol. 2014;2014:5 Article ID 257286.","journal-title":"J Ophthalmol"},{"issue":"12","key":"2689_CR29","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00417-010-1430-x","volume":"248","author":"H Nazari","year":"2010","unstructured":"Nazari H, Modarres M, Parvaresh MM, Ghasemi Falavarjani K. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol. 2010;248(12):1713\u20138.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2689_CR30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603\u201315.","journal-title":"N Engl J Med"},{"key":"2689_CR31","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/eye.2014.172","volume":"28","author":"YH Chen","year":"2014","unstructured":"Chen YH, Chen SN, Lien RI, et al. Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes. Eye (Lond). 2014;28:1080\u20136 quiz 1087.","journal-title":"Eye (Lond)"},{"key":"2689_CR32","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","volume":"122","author":"CK Hwang","year":"2015","unstructured":"Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis. Ophthalmology. 2015;122:1008\u201315.","journal-title":"Ophthalmology"},{"key":"2689_CR33","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","volume":"155","author":"BC Harder","year":"2013","unstructured":"Harder BC, Schlichtenbrede FC, von Baltz S, et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive errorresults. Am J Ophthalmol. 2013;155:1119-1124.e1111.","journal-title":"Am J Ophthalmol"},{"key":"2689_CR34","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck MM, Chuang AZ, Clark WL, et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol. 2014;132:1327\u20132133.","journal-title":"JAMA Ophthalmol"},{"key":"2689_CR35","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1056\/NEJMra1208129","volume":"367","author":"ME Hartnett","year":"2012","unstructured":"Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367:2515\u201326.","journal-title":"N Engl J Med"},{"key":"2689_CR36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1755-3768.2011.02351.x","volume":"91","author":"U Spandau","year":"2013","unstructured":"Spandau U, Tomic Z, Ewald U, et al. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol. 2013;91:170\u20135.","journal-title":"Acta Ophthalmol"},{"key":"2689_CR37","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","volume":"130","author":"J Hu","year":"2012","unstructured":"Hu J, Blair MP, Shapiro MJ, et al. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130:1000\u20136.","journal-title":"Arch Ophthalmol"},{"key":"2689_CR38","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","volume":"245","author":"EJ Chung","year":"2007","unstructured":"Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007;245:1727\u201330.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2689_CR39","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","volume":"248","author":"JY Lee","year":"2010","unstructured":"Lee JY, Chae JB, Yang SJ, et al. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol. 2010;248:1257\u201362.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2689_CR40","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/IAE.0b013e318296e26d","volume":"34","author":"J Kim","year":"2014","unstructured":"Kim J, Kim SJ, Chang YS, Park WS. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina. 2014;34:77\u201382.","journal-title":"Retina"},{"issue":"2","key":"2689_CR41","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0161-6420(99)00042-1","volume":"107","author":"MJ Banach","year":"2000","unstructured":"Banach MJ, Ferrone PJ, Trese MT. A comparison of dense versus less dense diode laser photocoagulation patterns for threshold retinopathy of prematurity. Ophthalmology. 2000;107(2):324\u20138.","journal-title":"Ophthalmology."},{"issue":"1","key":"2689_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1350-9462(02)00043-5","volume":"22","author":"AN Witmer","year":"2003","unstructured":"Witmer AN, Vrensen GFJM, van Noorden CJF, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22(1):1\u201329.","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"2689_CR43","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone i or posterior zone II. Retina. 2008;28(6):831\u20138.","journal-title":"Retina"},{"issue":"2","key":"2689_CR44","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1755-3768.2011.02351.x","volume":"91","author":"U Spandau","year":"2013","unstructured":"Spandau U, Tomic Z, Ewald U, Larsson E, \u00c5kerblom H, Holmstr\u00f6m G. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmologica. 2013;91(2):170\u20135.","journal-title":"Acta Ophthalmologica"},{"issue":"1","key":"2689_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","volume":"14","author":"JC Law","year":"2010","unstructured":"Law JC, Recchia FM, Morrison DG, Donahue SP, Estes RL. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS. 2010;14(1):6\u201310.","journal-title":"J AAPOS"},{"issue":"11","key":"2689_CR46","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","volume":"245","author":"EJ Chung","year":"2007","unstructured":"Chung EJ, Kim JH, Ahn HS, Koh HJ. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007;245(11):1727\u201330.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"2689_CR47","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.ophtha.2011.04.028","volume":"118","author":"DM Moshfeghi","year":"2011","unstructured":"Moshfeghi DM, Berrocal AM. Retinopathy of pre- maturity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology. 2011;118(7):1227\u20138.","journal-title":"Ophthalmology"},{"key":"2689_CR48","doi-asserted-by":"crossref","unstructured":"Seo E, Lee J. Functional and Structural Outcomes of Temporal Zone II-Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab in Retinopathy of Prematurity. Journal of Ophthalmology.\u00a02018, Article ID 2376240, 8 pages.","DOI":"10.1155\/2018\/2376240"},{"key":"2689_CR49","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10103-011-1021-z","volume":"28","author":"S Houston","year":"2013","unstructured":"Houston S, Wykoff C, Berrocal A, Hess D, Murray T. Laser treatment for retinopathy of prematurity. Lasers Med Sci. 2013;28:683\u201392.","journal-title":"Lasers Med Sci"},{"key":"2689_CR50","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJM199204163261603","volume":"326","author":"JT Flynn","year":"1992","unstructured":"Flynn JT, Bancalari E, Snyder ES, et al. A cohort study of transcutaneous oxygen tension and the incidence and severity of retinopathy of prematurity. N Engl J Med. 1992;326:1050\u20134.","journal-title":"N Engl J Med"},{"key":"2689_CR51","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1001\/archopht.1993.01090050052027","volume":"111","author":"MX Repka","year":"1993","unstructured":"Repka MX, Hardy RJ, Phelps DL, Summers CG. Surfactant prophylaxis and retinopathy of prematurity. Arch Ophthalmol. 1993;111:618\u201320.","journal-title":"Arch Ophthalmol"},{"issue":"suppl 1","key":"2689_CR52","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000243845","volume":"61","author":"TR Tubman","year":"1992","unstructured":"Tubman TR, Rankin SJ, Halliday HL, Johnson SS. Surfactant replacement therapy and the prevalence of acute retinopathy of prematurity. Biol Neonate. 1992;61(suppl 1):54\u20138.","journal-title":"Biol Neonate"},{"key":"2689_CR53","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1365-3016.1992.tb00747.x","volume":"6","author":"BA Darlow","year":"1992","unstructured":"Darlow BA, Horwood LJ, Clemett RS. Retinopathy of prematurity: risk factors in a prospective population-based study. Paediatr Perinat Epidemiol. 1992;6:62\u201380.","journal-title":"Paediatr Perinat Epidemiol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02689-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02689-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02689-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T06:47:03Z","timestamp":1669790823000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02689-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2689"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02689-0","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"assertion":[{"value":"29 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The entire protocol adhered to the tenets of the Declaration of Helsinkiand got approval with the institutional ethical committee. This study was performed with the approval of the ethics committee of Shiraz University of medical sciences (IR.SUMS.REC.1399.1302) Potential side effects were explained to parents before obtaining informed consent, and all parents agreed to participate in the research and informed consent were obtained from their parents.Full details of the trial protocol can be found at ExternalRef removed","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors has conflict of financial and non-financial interest with the submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"454"}}